GRL-0617是一種藥物,是最早被發現可作為木瓜蛋白酶樣蛋白酶(PLP)的選擇性小分子抑制劑的化合物之一,PLP可在某些致病病毒(包括冠狀病毒SARS-CoV-2)中發現。它已被證明可以在體外抑制病毒複製。[1][2][3][4]

GRL-0617
識別資訊
  • 5-amino-2-methyl-N-[(1R)-1-naphthalen-1-ylethyl]benzamide
CAS號1093070-16-6  checkY
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard英語CompTox Chemicals Dashboard (EPA)
化學資訊
化學式C20H20N2O
摩爾質量304.39 g·mol−1
3D模型(JSmol英語JSmol
  • CC1=C(C=C(C=C1)N)C(=O)N[C@H](C)C2=CC=CC3=CC=CC=C32
  • InChI=1S/C20H20N2O/c1-13-10-11-16(21)12-19(13)20(23)22-14(2)17-9-5-7-15-6-3-4-8-18(15)17/h3-12,14H,21H2,1-2H3,(H,22,23)/t14-/m1/s1
  • Key:UVERBUNNCOKGNZ-CQSZACIVSA-N

參見

編輯

參考文獻

編輯
  1. ^ Shin D, Mukherjee R, Grewe D, Bojkova D, Baek K, Bhattacharya A, et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature. November 2020, 587 (7835): 657–662. Bibcode:2020Natur.587..657S. PMC 7116779 . PMID 32726803. doi:10.1038/s41586-020-2601-5. 
  2. ^ Hajbabaie R, Harper MT, Rahman T. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease (PDF). Molecules. February 2021, 26 (4): 1134 [2022-12-12]. PMC 7924369 . PMID 33672721. doi:10.3390/molecules26041134 . (原始內容存檔 (PDF)於2022-12-12). 
  3. ^ Lim CT, Tan KW, Wu M, Ulferts R, Armstrong LA, Ozono E, et al. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp3 papain-like protease. The Biochemical Journal. July 2021, 478 (13): 2517–2531. PMC 8286840 . PMID 34198325. doi:10.1042/BCJ20210244. 
  4. ^ Xiang R, Yu Z, Wang Y, Wang L, Huo S, Li Y, et al. Recent advances in developing small-molecule inhibitors against SARS-CoV-2. Acta Pharmaceutica Sinica. B. July 2021. PMC 8260826 . PMID 34249607. doi:10.1016/j.apsb.2021.06.016.